Guo Jun, Yan Bin, An Xiao-Jing, Liu Sheng-Jing, Zhao Ming, Wang Fu, Guo Jun
Department of Andrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Zhonghua Nan Ke Xue. 2024 Jun;30(6):525-530.
To observe the effect and safety of the traditional Chinese medicine (TCM) Linggui Formula (LGF) in the treatment of asthenospermia with kidney deficiency and blood stasis.
This randomized controlled trial included 90 cases of asthenospermia with kidney deficiency and blood stasis treated in our hospital from September 2022 to September 2023, 45 by oral medication with LGF (the trial group) and the other 45 with oral levocarnitine solution (the control group), all for 12 weeks. We followed up the patients for 12 weeks, recorded the semen parameters, TCM syndrome scores, sexual hormone levels, pregnancy rates, and DNA fragmentation index (DFI) of the patients, and compared them between the two groups before and after treatment.
Totally, 82 of the patients completed the study, 42 in the trial and 40 in the control group. After treatment, the patients in the trial group showed significant increases in the percentage of progressively motile sperm (PMS) (from ［19.25±3.08］% to ［38.57±4.99］%, P< 0.05), total sperm motility (from ［32.29±3.64］% to ［46.50±4.77］%, P< 0.05) and sperm concentration (from ［83.9±37.2］ to ［95.1±34.9］× 10⁶/ml ］, P< 0.05), and so did the controls in PMS (from ［19.75±4.28］% to ［34.46±5.07］%, P< 0.05), total sperm motility (from ［33.02±4.93］% to ［43.11±4.72］%, P< 0.05) and sperm concentration (from ［85.2±39.7］ to ［88.1±35.2］ × 10⁶/ml , P< 0.05), all even more significant in the trial than in the control group (P< 0.05). No statistically significant difference was observed in the semen volume either in the trial (from ［3.38±0.38］ to ［3.24±0.45］ ml, P> 0.05) or in the control group (from ［3.46±0.52］ to ［3.30±0.37］ ml, P> 0.05), or between the trial and control groups (P> 0.05), or in the sexual hormone levels, pregnancy rates, and sperm DFI between the two groups before and after treatment (P> 0.05). Both groups of patients had good safety profiles without serious adverse reactions.
Linggui Formula can improve the percentage of PMS in asthenospermia patients with kidney deficiency and blood stasis, potentially enhancing pregnancy rates and with a good safety.
观察中药苓桂方治疗肾虚血瘀型弱精子症的疗效及安全性。
本随机对照试验纳入2022年9月至2023年9月在我院治疗的90例肾虚血瘀型弱精子症患者，其中45例口服苓桂方（试验组），另45例口服左卡尼汀溶液（对照组），均治疗12周。对患者随访12周，记录患者的精液参数、中医证候评分、性激素水平、妊娠率及精子DNA碎片指数（DFI），并比较两组治疗前后的情况。
共82例患者完成研究，试验组42例，对照组40例。治疗后，试验组患者的前向运动精子百分比（PMS）（从［19.25±3.08］%升至［38.57±4.99］%，P<0.05）、总精子活力（从［32.29±3.64］%升至［46.50±4.77］%，P<0.0
